{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:55:12Z","timestamp":1793962512464,"version":"4.8.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Abhimanyu Pandey"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research Bulletin"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.brainresbull.2020.12.018","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T11:39:01Z","timestamp":1609328341000},"page":"165-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies"],"prefix":"10.1016","volume":"168","author":[{"given":"Himika","family":"Wasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeta","family":"KH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainresbull.2020.12.018_bib0005","first-page":"242","article-title":"Presynaptic mechanisms of L-DOPA-induced dyskinesia: the findings, the debate, the therapeutic implications","volume":"5","author":"Angela Cenci","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ana.20045","article-title":"Axonal protection using flecainide in experimental autoimmune encephalomyelitis","volume":"55","author":"Bechtold","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0015","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.2042-7158.1994.tb03736.x","article-title":"The Anticonvulsant FCE 26743 is a selective and short acting MAO-B inhibitor devoid of inducing properties towards cytochrome p450 dependent testosterone hydroxylation in mice and rats","volume":"46","author":"Benedetti","year":"1994","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0020","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2147\/TCRM.S139545","article-title":"Safinamide in the management of patients with Parkinson\u2019s disease not stabilized on levodopa: a review of the current clinical evidence","volume":"14","author":"Bette","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2004.07.010","article-title":"Progress report on new antiepileptic drugs: a summary of the seventh EILAT conference (EILAT VII)","volume":"61","author":"Bialer","year":"2004","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0035","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","article-title":"Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fncel.2013.00157","article-title":"The role of dopamine signaling in epileptogenesis","volume":"7","author":"Bozzi","year":"2013","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0050","series-title":"Tertiary Pharmacology Review","author":"Brown","year":"2016"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0055","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1212\/WNL.67.7_suppl_2.S18","article-title":"Safinamide: from molecular targets to a new anti-Parkinson drug","volume":"67","author":"Caccia","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0060","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/j.2040-4603.2015.tb00630.x","article-title":"Channelopathies of skeletal muscle excitability","volume":"5","author":"Cannon","year":"2015","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0065","first-page":"546","article-title":"Principles, examples and clinical consequences","volume":"109","author":"Cascorbi","year":"2012","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00002826-200307000-00012","article-title":"Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition","volume":"26","author":"Cattaneo","year":"2003","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0075","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3233\/JPD-171143","article-title":"Long-term effects of safinamide on mood fluctuations in Parkinson\u2019s disease","volume":"7","author":"Cattaneo","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0080","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12325-018-0687-z","article-title":"Long-term efficacy of safinamide on Parkinson\u2019s disease chronic pain","volume":"35","author":"Cattaneo","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/JPD-191765","article-title":"Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson\u2019s disease patients","volume":"10","author":"Cattaneo","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0090","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev-pharmtox-011112-140232","article-title":"Sodium channels, inherited epilepsy, and antiepileptic drugs","volume":"54","author":"Catterall","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0095","series-title":"List of New Drugs Approved in the Year 2019 Till Date \u2013 CDSCO","author":"CDSCO [Internet]","year":"2019"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0100","first-page":"809","article-title":"Safinamide (Newron Pharmaceuticals)","volume":"2","author":"Chazot","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0105","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0006-291X(84)91293-2","article-title":"Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase","volume":"120","author":"Chiba","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0110","doi-asserted-by":"crossref","DOI":"10.5772\/64456","article-title":"Antiepileptic drug targets: an update on ion channels","author":"Chindo","year":"2016","journal-title":"Epileptology"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0115","series-title":"Committee for Medicinal Products for Human Use (CHMP) Assessment Report","author":"CHMP","year":"2014"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0120","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/glia.20112","article-title":"Sodium channels contribute to microglia\/macrophage activation and function in EAE and MS","volume":"49","author":"Craner","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0125","first-page":"622","article-title":"Xadago (Safinamide) a monoamine oxidase-B inhibitor for the adjunct treatment of motor symptoms in Parkinson\u2019s disease","volume":"42","author":"Cruz","year":"2017","journal-title":"P T"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0130","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","article-title":"The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson\u2019s disease","volume":"122","author":"Damier","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0135","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40265-015-0389-7","article-title":"Safinamide: first global approval","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.expneurol.2020.113287","article-title":"Safinamide\u2019s potential in treating nondystrophic myotonias: inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo","volume":"328","author":"Desaphy","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0145","doi-asserted-by":"crossref","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0150","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00210-011-0674-2","article-title":"Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers","volume":"384","author":"Di Stefano","year":"2011","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-510X(98)00258-5","article-title":"Evidence of oxidative stress in mdx mouse muscle: studies of the pre- necrotic state","volume":"161","author":"Disatnik","year":"1998","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0160","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMx140041","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"371","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/med.2610090104","article-title":"Interactions of monoamine oxidase with substrates and inhibitors","volume":"9","author":"Dostert","year":"1989","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0170","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0924-977X(91)90545-6","article-title":"New anticonvulsants with selective MAO-B inhibitory activity","volume":"1","author":"Dostert","year":"1991","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0175","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/exnr.1997.6431","article-title":"Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression","volume":"144","author":"Duty","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0180","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.autneu.2008.03.003","article-title":"Cardiovascular responses to electrical stimulation of sympathetic nerves in the pithed mouse","volume":"140","author":"Elayan","year":"2008","journal-title":"Auton. Neurosci. Basic Clin."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0190","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-2999(89)90790-5","article-title":"Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists","volume":"168","author":"Engber","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0195","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/nmt-2016-0022","article-title":"Clinical pharmacology review of opicapone for the treatment of Parkinson\u2019s disease","volume":"6","author":"Fabbri","year":"2016","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0200","doi-asserted-by":"crossref","first-page":"18168","DOI":"10.3390\/molecules201018168","article-title":"Duchenne muscular dystrophy: from diagnosis to therapy","volume":"20","author":"Falzarano","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0205","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nurt.2006.11.011","article-title":"Safinamide","volume":"4","author":"Fariello","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0022-3565(24)37430-0","article-title":"Preclinical evaluation of PNU-151774E as a novel anticonvulsant","volume":"285","author":"Fariello","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0920-1211(99)00103-5","article-title":"Acute behavioral and EEG effects of NW-1015 on electrically-induced after discharge in conscious monkeys","volume":"39","author":"Fariello","year":"2000","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0220","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0225","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0230","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/jpet.118.251645","article-title":"Safinamide modulates striatal glutamatergic signalling in a rat model of levodopa-induced dyskinesia","volume":"367","author":"Gardoni","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0235","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3389\/fphys.2018.01087","article-title":"Drug repurposing for Duchenne Muscular Dystrophy: the monoamine oxidase B inhibitor safinamide ameliorates the pathological phenotype in mdx mice and in myogenic cultures from DMD patients","volume":"9","author":"Gargioli","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0240","series-title":"Australian Public Assessment Report for Safinamide about the Therapeutic Goods Administration (TGA)","author":"Goods Administration","year":"2019"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0245","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial","volume":"384","author":"Gray","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0250","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.parkreldis.2013.01.009","article-title":"Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys","volume":"19","author":"Gr\u00e9goire","year":"2013","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0255","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nn.3934","article-title":"Animal models in epilepsy research: legacies and new directions","volume":"18","author":"Grone","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0260","series-title":"Draft Guidance","article-title":"Multiple endpoints in clinical trials guidance for industry","author":"Hills","year":"2017"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0265","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0270","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.51.2_Suppl_2.S2","article-title":"Biochemical aspects of Parkinson\u2019s disease","volume":"51","author":"Hornykiewicz","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0275","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fphar.2016.00121","article-title":"Therapeutic approaches to genetic ion channelopathies and perspectives in drug discovery","volume":"7","author":"Imbrici","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0280","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng1270","article-title":"Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency","volume":"35","author":"Irwin","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0285","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nm.3639","article-title":"GABA from reactive astrocytes impairs memory in mouse models of Alzheimer\u2019s disease","volume":"20","author":"Jo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0290","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1474-4422(19)30034-1","article-title":"Global, regional, and national burden of stroke, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Johnson","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/7854_2014_352","article-title":"Symptomatic models of Parkinson\u2019s disease and L-DOPA-induced dyskinesia in non-human primates","volume":"22","author":"Johnston","year":"2014","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0300","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mds.25273","article-title":"Novel nondopaminergic targets for motor features of Parkinson\u2019s disease: review of recent trials","volume":"28","author":"Kalia","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0305","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/17512433.2014.968555","article-title":"Safinamide for the treatment of Parkinson\u2019s disease","volume":"7","author":"Kandadai","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0310","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/NDT.S50371","article-title":"Animal models of epilepsy: use and limitations","volume":"10","author":"Kandratavicius","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0315","series-title":"Clinical Review Application Type NDA","author":"Kapcala","year":"2017"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0320","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jns.2008.03.019","article-title":"Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine","volume":"274","author":"Kapoor","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0325","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1101\/cshperspect.a022871","article-title":"Potassium channels in epilepsy","volume":"6","author":"Kohling","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0330","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/bdd.1822","article-title":"Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects","volume":"33","author":"Krosser","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0335","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1169096","article-title":"Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice","volume":"323","author":"Kuchibhotla","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0340","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14728214.12.3.407","article-title":"Emerging drugs for epilepsy","volume":"12","author":"Kwan","year":"2007","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0345","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.1184334","article-title":"Channel-mediated tonic GABA release from glia","volume":"330","author":"Lee","year":"2010","journal-title":"Science."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0350","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000354805","article-title":"Disposition and metabolism of safinamide, a novel drug for Parkinson\u2019s disease, in healthy male volunteers","volume":"92","author":"Leuratti","year":"2013","journal-title":"Pharmacology"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0355","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1073\/pnas.79.20.6385","article-title":"Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons","volume":"79","author":"Levitt","year":"1982","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0360","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.251","article-title":"Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson\u2019s disease","volume":"4","author":"Loprete","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0365","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1528-1157.1993.tb05918.x","article-title":"Antiepileptic drug mechanisms of action","volume":"34","author":"Macdonald","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0370","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-2999(98)00554-8","article-title":"PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat","volume":"359","author":"Maj","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0375","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1528-1157.1999.tb02035.x","article-title":"Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures","volume":"40","author":"Maj","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0380","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0385","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer\u2019s disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0390","first-page":"450","article-title":"The effect of safinamide, a novel drug for Parkinson\u2019s disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial","volume":"92","author":"Marquet","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0395","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mds.870090112","article-title":"Unified Parkinson\u2019s disease rating scale characteristics and structure","volume":"9","author":"Mart\u00ednez-Mart\u00edn","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0400","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2003.12.004","article-title":"Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity","volume":"50","author":"Marzo","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0405","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1093\/hmg\/ddq339","article-title":"Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy","volume":"19","author":"Menazza","year":"2010","journal-title":"Human Mol. Genet."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0410","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.3390\/biom5043112","article-title":"Overview of glutamatergic dysregulation in central pathologies","volume":"5","author":"Miladinovic","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0415","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/awt041","article-title":"Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis","volume":"136","author":"Morsali","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0420","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/17425255.2017.1329418","article-title":"Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson\u2019s disease","volume":"13","author":"Muller","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0425","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of Safinamide","volume":"56","author":"M\u00fcller","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0430","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00307697","article-title":"Expression of monoamine oxidase B activity in astrocytes of senile plaques","volume":"80","author":"Nakamura","year":"1990","journal-title":"Acta Neuropath."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0435","first-page":"S13","article-title":"The evolution and origin of motor complications in Parkinson\u2019s disease","volume":"55","author":"Obeso","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0440","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1517\/13543784.17.7.1115","article-title":"An expert opinion on safinamide in Parkinson\u2019s disease","volume":"17","author":"Onofrj","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0445","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(16)31320-4","article-title":"Progressive multiple sclerosis : prospects for disease therapy, repair, and restoration of function","volume":"389","author":"Ontaneda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0450","doi-asserted-by":"crossref","first-page":"eaav0316","DOI":"10.1126\/sciadv.aav0316","article-title":"Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer\u2019s disease","volume":"5","author":"Park","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0455","series-title":"Successful Drug Discovery","first-page":"383","article-title":"Discovery and development of safinamide, a new drug for the treatment of Parkinson\u2019s disease","author":"Pevarello","year":"2018"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0460","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/00304949609356519","article-title":"Reductive alkylation of \u03b1-aminoamides","volume":"28","author":"Pevarello","year":"1996","journal-title":"Org. Prep. Proced. Int."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0465","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/S0960-894X(99)00415-1","article-title":"Sodium channel activity and sigma binding of 2-aminopropanamide anticonvulsants","volume":"9","author":"Pevarello","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0470","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1460-9568.1996.tb01603.x","article-title":"Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies","volume":"8","author":"Piallat","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0475","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.conb.2005.05.010","article-title":"Function and dysfunction of synaptic calcium channels: insights from mouse models","volume":"15","author":"Pietrobon","year":"2005","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108006","article-title":"Safinamide inhibits in vivo glutamate release in a rat model of Parkinson\u2019s disease","volume":"167","author":"Pisan\u00f2","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0485","first-page":"1","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0490","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3389\/fneur.2020.00686","article-title":"Perspective: current pitfalls in the search for future treatments and prevention of Parkinson\u2019s disease","volume":"11","author":"Poortvliet","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0495","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0896-6273(00)81203-9","article-title":"Selective depression of low-release probability excitatory synapses by sodium channel blockers","volume":"26","author":"Prakriya","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0500","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/17460441.2018.1437142","article-title":"The development of biological therapies for neurological diseases: moving on from previous failures","volume":"13","author":"Qosa","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0505","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1080\/00207454.2016.1275617","article-title":"Physical therapy and occupational therapy in Parkinson\u2019s disease","volume":"127","author":"Radder","year":"2017","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0510","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022723","article-title":"The role of calcium channels in epilepsy","volume":"6","author":"Rajakulendran","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0515","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0022-3565(25)23492-9","article-title":"Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain","volume":"249","author":"Riachi","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.018_bib0520","first-page":"27","article-title":"Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid; Preliminary report of representative cases","volume":"13","author":"Robitzek","year":"1952","journal-title":"Q. Bull. Sea View Hosp."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0525","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMp1701047","article-title":"The failure of solanezumab\u2014how the FDA saved taxpayers billions","volume":"376","author":"Sacks","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0530","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/nan.12263","article-title":"Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson\u2019s disease","volume":"42","author":"Sadeghian","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0535","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0022-3565(24)38068-1","article-title":"Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound","volume":"288","author":"Salvati","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0540","first-page":"467","article-title":"Medical management of epileptic seizures: challenges and solutions","volume":"12","author":"Sarma","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0545","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1523\/JNEUROSCI.12-05-01977.1992","article-title":"Quantitative enzyme radioautography with 3H-Ro 41\u20131049 and 3H-Ro 19\u20136327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain","volume":"12","author":"Saura","year":"1992","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0550","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0306-4522(94)90311-5","article-title":"Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography","volume":"62","author":"Saura","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0555","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00023210-199504060-00009","article-title":"Review of the mechanisms of action of antiepileptic drugs","volume":"4","author":"Schachter","year":"1995","journal-title":"CNS Drugs"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0560","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1468-1331.2012.03840.x","article-title":"Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson\u2019s disease","volume":"20","author":"Schapira","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0565","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations a randomized clinical trial","volume":"74","author":"Schapira","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0570","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying the response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0575","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40263-013-0097-3","article-title":"Current place of monoamine oxidase inhibitors in the treatment of depression","volume":"27","author":"Shulman","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0580","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/npp.2011.212","article-title":"Parkinson\u2019s disease therapeutics: new developments and challenges since the introduction of levodopa","volume":"37","author":"Smith","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0585","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1535-7511.2007.00156.x","article-title":"Persistent sodium current and its role in epilepsy","volume":"7","author":"Stafstrom","year":"2007","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0590","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1212\/01.WNL.0000134672.44217.F7","article-title":"Improvement of motor function in early Parkinson disease by safinamide","volume":"63","author":"Stocchi","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0595","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archneur.62.6.905","article-title":"Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study","volume":"62","author":"Stocchi","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0600","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1212\/WNL.67.7_suppl_2.S24","article-title":"Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition","volume":"67","author":"Stocchi","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0605","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004647-199801000-00002","article-title":"Anoxic and ischemic injury of myelinated axons in CNS white matter: from mechanistic concepts to therapeutics","volume":"18","author":"Stys","year":"1998","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0610","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1523\/JNEUROSCI.12-02-00430.1992","article-title":"Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na+-Ca2+ exchanger","volume":"12","author":"Stys","year":"1992","journal-title":"J. Neurosci."},{"issue":"Suppl. 29","key":"10.1016\/j.brainresbull.2020.12.018_bib0615","first-page":"269","article-title":"The interactions of monoamine oxidase with some derivatives of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","author":"Sullivan","year":"1990","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0620","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.drudis.2018.01.033","article-title":"Safinamide: a new hope for Parkinson\u2019s disease?","volume":"23","author":"Teixeira","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0625","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1111\/febs.12142","article-title":"Oxidative stress and pathology in muscular dystrophies: focus on protein thiol oxidation and dysferlinopathies","volume":"280","author":"Terrill","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0630","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","article-title":"Multiple sclerosis: an immune or neurodegenerative disorder?","volume":"31","author":"Trapp","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0635","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3565(25)11858-2","article-title":"Effect of iproniazid on serotonin metabolism in vivo","volume":"120","author":"Udenfriend","year":"1957","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"18","key":"10.1016\/j.brainresbull.2020.12.018_bib0640","first-page":"S0213","article-title":"Spanish expert consensus on the use of safinamide in Parkinson\u2019s disease","author":"Valldeoriola","year":"2018","journal-title":"Neurologia"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0645","first-page":"239","article-title":"Anticonvulsant activity of milacemide","volume":"266","author":"Van Dorsser","year":"1983","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0650","unstructured":"WHOCC-ATC\/DDD Index [Internet], 2019. https:\/\/www.whocc.no\/atc_ddd_index\/?code=N04BD03 (Accessed May 7, 2020)."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0655","first-page":"9","article-title":"Functional neuroanatomy of the basal ganglia in Parkinson\u2019s disease","volume":"91","author":"Wichmann","year":"2003","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0660","first-page":"S3","article-title":"Levodopa therapy for Parkinson disease: a look backward and forward","volume":"86","author":"Witt","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0665","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1747-4949.2012.00839.x","article-title":"Pathophysiologic cascades in ischemic stroke","volume":"7","author":"Xing","year":"2012","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0670","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s12640-020-00246-5","article-title":"The protective effect of safinamide in ischemic stroke mice and a brain endothelial cell line","volume":"38","author":"Xu","year":"2020","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0675","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1756-6606-4-42","article-title":"The amount of astrocytic GABA positively correlates with the degree of tonic inhibition in hippocampal CA1 and cerebellum","volume":"4","author":"Yoon","year":"2011","journal-title":"Mol. Brain"},{"issue":"Suppl. 1","key":"10.1016\/j.brainresbull.2020.12.018_bib0680","first-page":"S287","article-title":"Monoamine oxidase: isoforms and inhibitors in Parkinson\u2019s disease and depressive illness","volume":"147","author":"Youdim","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0685","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1124\/dmd.118.084905","article-title":"Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and drug administration in 2017 s","volume":"47","author":"Yu","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0690","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00415-014-7391-y","article-title":"Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: a systematic review","volume":"262","author":"Zaccara","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.018_bib0695","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF02174413","article-title":"Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes","volume":"8","author":"Zeller","year":"1952","journal-title":"Experientia"}],"container-title":["Brain Research Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0361923020307358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0361923020307358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:43:40Z","timestamp":1759783420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0361923020307358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":139,"alternative-id":["S0361923020307358"],"URL":"https:\/\/doi.org\/10.1016\/j.brainresbull.2020.12.018","relation":{},"ISSN":["0361-9230"],"issn-type":[{"value":"0361-9230","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies","name":"articletitle","label":"Article Title"},{"value":"Brain Research Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainresbull.2020.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}